W. BARRY WOOD JR., M.D.; PERRIN H. LONG, M.D.
This content is PDF only. Please click on the PDF icon to access.
It has been established by a number of investigators1, 2, 3, 4, 5 that sulfapyridine exercises a bacteriostatic effect upon pneumococci in vitro. Fleming1 has shown that the growth of pneumococci in human whole blood is inhibited by sulfapyridine, but that in the absence of leukocytes the organisms are not destroyed. When leukocytes are present in the blood-sulfapyridine preparations, the growth of pneumococci is not only inhibited, but in many instances the blood is rendered sterile, probably as a result of the combined action of the sulfapyridine and the natural antibacterial substances in the serum. If type-specific pneumococcal antiserum is
WOOD WB, LONG PH. OBSERVATIONS UPON THE EXPERIMENTAL AND CLINICAL USE OF SULFAPYRIDINE. III. THE MECHANISM OF RECOVERY FROM PNEUMOCOCCAL PNEUMONIA IN PATIENTS TREATED WITH SULFAPYRIDINE1. Ann Intern Med. 1939;13:612–617. doi: 10.7326/0003-4819-13-4-612
Download citation file:
Published: Ann Intern Med. 1939;13(4):612-617.
Infectious Disease, Pneumonia, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use